Holen Sie sich die Stockscreener-App
132.90
0.29%
-0.39
Handel nachbörslich:
132.88
-0.02
-0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$133.29
Offen:
$133.69
24-Stunden-Volumen:
6.29M
Relative Volume:
0.91
Marktkapitalisierung:
$164.96B
Einnahmen:
$29.45B
Nettoeinkommen (Verlust:
$8.51B
KGV:
19.60
EPS:
6.7823
Netto-Cashflow:
$9.46B
1W Leistung:
-4.92%
1M Leistung:
-3.14%
6M Leistung:
+9.42%
1J Leistung:
+25.96%
1-Tages-Spanne:
$131.34
$134.07
1-Wochen-Bereich:
$131.34
$140.26
52-Wochen-Spanne:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
132.90 | 165.44B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
921.48 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
226.10 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
200.50 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
194.81 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
147.32 | 282.35B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral - MedCity News
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Yahoo Finance UK
GILD (Gilead Sciences Inc.) reports narrow Q4 2025 earnings beat and mild revenue growth, shares dip slightly.Open Stock Signal Network - Cổng thông tin điện tử Tỉnh Sơn La
Gilead Sciences stock price forecast: limited upside as GILD trades near support after weekly decline - Traders Union
Gilead set to report as Yeztugo launch, M&A strategy face test - Investing.com India
Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Merck steps up as ‘meaningful competitor’ to Gilead with HIV pill approval - BioSpace
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 - GlobeNewswire Inc.
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - Yahoo Finance
Release of 2025 impact report weighs on Gilead Sciences stock amid oversold momentum signals - Traders Union
Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026? - TIKR.com
7,568 Shares in Gilead Sciences, Inc. $GILD Acquired by Ticino Wealth - MarketBeat
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls - BioSpace
Gilead Sciences : Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions - marketscreener.com
Arcus pulls another TIGIT trial as Gilead steps back - The Pharma Letter
Zacks Research Predicts Lower Earnings for Gilead Sciences - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Analysis: A Healthcare Giant with a 15% Upside Potential - DirectorsTalk Interviews
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance
Lobbying Update: $3,190,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 EarningsBut Won't (NASDAQ:GILD) - Seeking Alpha
Leerink cuts Arcus Biosciences stock price target on Gilead collaboration end - Investing.com Canada
Gilead Sciences stock edges lower as company discusses expanding oncology reach at AACR26 - Traders Union
Arcus halts Gilead-partnered late-stage trial (RCUS:NYSE) - Seeking Alpha
Arcus Ends Key Lung Cancer Trials in Gilead Partnership Reset - TipRanks
Arcus Biosciences ends STAR-121 lung cancer study and updates Gilead collaboration - Investing.com
Arcus Biosciences Incdiscontinues phase 3 star-121 study with Gilead due to futility - marketscreener.com
Zurcher Kantonalbank Zurich Cantonalbank Purchases 19,741 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Lowered by Miller Howard Investments Inc. NY - MarketBeat
Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability - ChartMill
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Gilead Sciences, Inc. (GILD) is a trending stock: Facts to know before betting on it - MSN
Gilead Deepens Oncology Reach And HIV Prevention With Arcellx And Lenacapavir - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Acquired by AE Wealth Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by GF Fund Management CO. LTD. - MarketBeat
Gilead Sciences, Inc. $GILD Position Raised by Asset Management One Co. Ltd. - MarketBeat
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview - Insider Monkey
Jim Cramer on Gilead Sciences: “I’d Hold On to It” - Insider Monkey
Gilead Sciences stock edges lower as research teams attend AACR26 to advance cancer therapies - Traders Union
Gilead (GILD) Extends Tender Offer for Arcellx (ACLX) to April 2 - GuruFocus
Gilead extends Arcellx tender offer again - MSN
Gilead Sciences (NASDAQ:GILD) Given New $130.00 Price Target at The Goldman Sachs Group - MarketBeat
Morgan Stanley Adjusts Gilead Sciences, Inc. (GILD) Outlook Ahead of Q1 Earnings - Insider Monkey
Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating - Moomoo
Gilead extends Arcellx tender offer again (GILD:NASDAQ) - Seeking Alpha
Gilead Sciences (NASDAQ: ACLX) offers $115 per share plus CVR; deadline extended - Stock Titan
Gilead Sciences patents new GTPase KRAS G12D inhibitors - BioWorld News
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating - Moomoo
Gilead extends Arcellx tender offer to April 27 - Investing.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Apr 15 '26 |
Sale |
140.96 |
3,000 |
422,880 |
128,779 |
0.68%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):